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Analysis of the disaccharides derived from
hyaluronic acid and chondroitin sulfate by capillary
electrophoresis with sample stacking
CE conditions for monitoring the unsaturated disaccharides of hyaluronic acid (di-HA)
and chondroitin sulfate (di-CS) using an alkaline tetraborate buffer, electrokinetic
sample injection, and UV absorption detection at 232 nm are reported. Separations
were performed in an uncoated fused-silica capillary having reversed polarity and
reversed electroosmosis generated with the addition of CTAB to the buffer. The
influence of various separation parameters, including the concentration of CTAB, buf-
fer pH, concentration of tetraborate, and applied voltage, on the resolution of the two
disaccharides was investigated. Baseline separation was obtained with 25 mM tetra-
borate at pH 10.0 and having 0.05 mM CTAB. Chloride and phosphate in the sample
are beneficial for the stacking of the disaccharides, with di-HA forming a much shar-
per peak than di-CS. Using samples prepared in 25 mM Tris-HCl (pH 7.5) and elec-
trokinetic injection at the cathode at –10 kV for 40 s, linear relationships between the
corrected peak area and the concentration of the disaccharides have been found in
the ranges of 1.0–400.0 and 0.1–1.0 lg/mL (0.2–1.0 lg/mL for di-CS), with correla-
tion coefficients being A0.9933 in all cases. The RSDs of detection times and correc-
ted peak areas were between 1.13–1.24 and 1.57–2.13%, respectively. Applied to
human serum samples that were prepared by ethanol precipitation and depolymeriza-
tion of the two polysaccharides with chondroitinase ABC reveals comigration of endo-
genous compounds with di-HA and a sample-dependent detection time. The di-HA
content in the serum sample can be estimated via subtraction of the blank peak that
is obtained without enzymatic hydrolysis.
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1 Introduction
Hyaluronic acid (HA) comprises negatively charged, lin-
ear polysaccharides composed of a variable number of
repeating disaccharide units containing one hexosamine
(b-(1fi3)-N-acetylglycosamine) and one uronic acid (b-
(1fi4)-glucuronic acid). Together with heparin, heparin
sulfate, dermatan sulfate, keratan sulfate, and chondroitin
sulfate (CS), it forms the group of connective tissue poly-
saccharides known as glycosaminoglycans (GAGs). HA
has a high molecular mass (up to 86106 Da correspond-
ing to about 10 000 disaccharide units), is not sulfated,
and is not covalently bound to proteins [1–6]. HA is mainly
produced by fibroblasts and other specialized connective
tissue cells and participates in various cell-to-cell interac-
tions. It is found extensively throughout the human body,
being most abundant in loose connective tissues, such as
the umbilical cord, synovial fluid, and vitreous body of the
eye [7]. Synovial HA may pass into plasma via the lym-
phatic system [8]. In circulation, HA levels are maintained
by an efficient receptor-dependent removal mechanism
present in sinusoidal endothelial cells of the liver and by
the enzymatic action of hyaluronidase [9]. Increased pro-
duction of HA in the connective tissue surrounding the
joints is stimulated by various inflammatory conditions
and thus can be used to monitor joint condition [10, 11].
Increased serum HA levels may also arise from various
liver diseases characterized by liver fibrosis and cirrhosis,
due to decreased hepatic removal and/or increased hepa-
tic production of HA during liver inflammation [12, 13].
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The determination of serum HA levels is useful for asses-
sing the degree of liver fibrosis and for monitoring liver
function [13–16] and thus is a topic of high interest for the
treatment of patients in our departmental hepatology out-
patient clinic. Monitoring serum HA is also used in other
areas, such as in septic conditions, tumor growth (such as
Wilm's tumor and malignant mesothelioma), and for the
diagnosis of rare hereditary diseases (such as Werner’s
syndrome and cutaneous hyaluronanosis) [4]. Many
different colorimetric, chromatographic, and electrophore-
tic methods have been developed for the analysis of HA
and other GAGs, their metabolic products, and the
degraded molecules thereof [1, 2]. Serum HA is currently
determined with assays that are based upon the specific
affinity of certain proteins to HA and that feature a low
lg/L sensitivity [17], most notably a radiometric method
(HA-test, Pharmacia, Uppsala, Sweden) and a sandwich
enzyme-binding assay (Chugai Pharmaceutical, Tokyo,
Japan; HA-test, Corgenix, Westminster, CO, USA). The
radiometric assay measures the reactivity of the unbound
reagent after removal from the sample using Sepharose-
bound HA, while the enzyme-binding assay immobilizes
HA to the surface of a microtiter well and uses an enzyme-
tagged protein that is subsequently bound to the immobil-
ized HA and catalyzes a color reaction that can be meas-
ured via absorbance at 450 nm. Both methods suffer from
the tedious and laborious nature of the procedure, which
prompted us to begin to search for new, more instrumental
possibilities that are suitable to measure either entire or
degraded HAmolecules in human serum.
CE in its various modes is increasingly employed in the
separation and analysis of a wide variety of carbohy-
drates, including HA and its degraded molecules [18–20].
CE with direct and indirect UV absorption detection has
been applied to the analysis of intact HA in pharmaceuti-
cal semisolid formulations [21], in human and bovine vitr-
eous humor [22], and in human synovial fluid [23]. CE has
been used in determining the physical properties of intact
HA by the addition of a polymeric matrix, such as pullan
and polyethyleneglycol, to the separation electrolyte [24,
25]. HA of synovial fluid has been determined by CE after
hydrolysis of the polymeric hyaluronan to the tetrasac-
charide by the action of testicular hyaluronidase [23]. In
other approaches, HA in effusions from human malignant
mesothelioma [26] and in skin and other tissue samples of
various species [27] has been degraded with chondroiti-
nase ABC to the disaccharide a-4-deoxy-L-threo-hex-4-
enopyranosyluronic acid-(1fi3)-N-acetyl-D-glucosamine
(di-HA, for chemical structure see Fig. 1) prior to analysis
of di-HA by CE. Degradation of HA and CS with chondroi-
tinase ABC is preferred as the resulting disaccharides, di-
HA, and the nonsulfated disaccharide of CS, a-4-deoxy-L-
threo-hex-4-enopyranosyluronic acid-(1fi3)-N-acetyl-D-
galactosamine (di-CS, for chemical structure refer to
Fig. 1), contain unsaturated uronic acid residues at their
nonreducing end allowing sensitive detection at 232 nm
[1–3, 19, 26, 27]. This method has also been applied to
the determination of HA of gastrointestinal carcinomas
[28], and the CE analysis of GAG-derived disaccharides
in biological samples has been reviewed by Lamari et al.
[3]. HA has no unsaturated glucuronic acid and can thus
only be detected at 190–200 nm, an approach that pro-
vides lower sensitivity and is prone to more interferences
when analyzing biological samples.
Up to now, CE has never been used to analyze HA in
human serum. The rather low HA concentration in serum
(a100 ng/mL determined with the two routine assays in
healthy subjects) requires efficient sample-stacking tech-
niques for CE detection of intact or digested HA in serum.
Human serum contains a high concentration of salts and
this precludes online preconcentration techniques based
on conventional sample-stacking or field-enhanced sam-
ple injection which require low salt matrices for efficient
analyte focusing. Transient ITP or sample self-stacking
[29–34], formation of a transient moving chemical reaction
boundary [35], sweeping [36–38], and use of a dynamic
pH junction [39], however, are online concentration tech-
niques that can be used to temporarily induce narrow ana-
lyte bands in the presence of large amounts of salts.
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Figure 1. Chemical structures of the unsaturated disacchar-
ide of HA (di-HA) and the unsaturated nonsulfated disac-
charide of CS (di-CS) derived from HA and CS, respectively,
through the action of chondroitinase ABC. NHAc refers to
the N-acetyl group of the hexosamine moiety.
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In the present study, electrokinetic sample injection
together with sample stacking was studied for high-sensi-
tivity analysis of di-HA and di-CS in model mixtures and
human serum digested by chondroitinase ABC using a
borate buffer at alkaline pH, reversed electroosmosis
(EO) provided by addition of CTAB, and direct UV detec-
tion at 232 nm. First, the effects of pH and concentration
of the buffer, the CTAB concentration, and the separation
voltage were examined. Then, the influence of injection
time on resolution, peak area, peak height, corrected
peak area, and theoretical plates was studied, and the
impact of the chloride and phosphate concentration in the
sample on sample stacking was investigated. The opti-
mized method was applied to the determination of di-HA
in sera of healthy humans.
2 Experimental
2.1 Reagents and solutions
All chemicals used were of analytical grade. HA (H-1751,
as potassium salt, from human umbilical cord that con-
tains small amounts of CS), di-HA (sodium salt), di-CS
(sodium salt), and CTAB were purchased from Sigma (St.
Louis, MO, USA). Boric acid, disodium tetraborate deca-
hydrate, and ethanol (absolute) were from Merck (Darm-
stadt, Germany), and chondroitinase ABC from Proteus
vulgaris (EC 4.2.2.4) was from Fluka (Buchs, Switzer-
land). A stock solution of the disaccharides of HA and CS
was prepared in water (1.0 mg/mL each) and aliquots
thereof were used to provide solutions containing 0.10,
0.20, 0.50, 1.0, 2.0, 5.0, 10.0, 20.0, 50.0, 100.0, 200.0,
400.0 lg/mL of di-HA and di-CS in 25 mM Tris-HCl
(pH 7.5).
2.2 Instrumentation and running conditions
CE was performed on the Beckman P/ACE 5510 system
(Beckman Instrument, Fullerton, CA, USA) that was
equipped with a fused-silica capillary of 75 lm ID667 cm
(60 cm to the detector; Polymicro Technologies, Phoenix,
AZ, USA), which was mounted in a cartridge with a
1006800 lmaperture (Beckman). Prior to each injection,
the capillary was successively rinsed with 1.0 mol/L
NaOH for 2 min, distilled water for 2 min, and finally with
running buffer for 3 min. If not stated otherwise, samples
were injected electrokinetically at –10 kV for 40 s and
separated at –12 kV. The temperature of the cooling fluid
was set at 258C. Detection by UV absorbance occurred at
232 nm. If not stated otherwise, the running buffer was
composed of 25 mM disodium tetraborate that was
titrated to pH 10.0 by addition of 1.0 M NaOH and con-
tained 0.05 mMCTAB. All experiments were done in tripli-
cate.
2.3 Serum sample treatment
The first part of the sample pretreatment is similar to that
employed for the analysis of HA in effusions from human
malignant mesothelioma [26]. Ten milliliters of absolute
ethanol was added to 1 mL of serum and precipitation was
completed overnight at 48C. The precipitate was recov-
ered by centrifugation using an Eppendorf microcentri-
fuge (15 000g for 5 min) and was dried at 408C under a
gentle stream of air. HA was digested via addition of
800 lL of chondroitinase ABC in 25 mM Tris-HCl (pH 7.5,
0.5 U/mL of enzyme solution) to the dried residue and
incubated for 90 min at 378C. Two milliliters of ethanol
was added to the digested solution to precipitate the pro-
teins and nondegraded polysaccharides. After centrifuga-
tion (3500g for 5 min), the supernatant was decanted into
a clean glass tube, evaporated to dryness at 408C under a
gentle stream of air, reconstituted in 100 lL bidistilled
water, and stored at –208C. The preparation of the blank
serum sample was identical except that the 800 lL of
25 mM Tris-HCl (pH 7.5) added for the incubation did not
contain any enzyme.
3 Results and discussion
3.1 Separation of disaccharides of HA andCS
The CE determination of HA in serum as di-HA produced
by depolymerization of HA with chondroitinase ABC
requires the separation of the two similar nonsulfated dis-
accharides, di-HA and di-CS (as presented in Fig. 1), as
well as sulfated disaccharides of CS. It is not difficult to
separate the nonsulfated disaccharides from the disac-
charides with monosulfate and disulfate since the charge-
to-mass ratio is significantly different [26]. The electro-
phoretic separation of the two nonsulfated disaccharides
(di-HA and di-CS), however, is a challenge as they have
an identical net charge and the charge is located at the
same position in each molecule. The only difference
between these two disaccharides is the equatorial (di-HA)
or axial (di-CS) position of the hydroxyl function on carbon
4 of the hexosamine residue (Fig. 1). Using the acidic
phosphate buffer and reversed polarity as described in
[26], the two disaccarides could not be detected in our
laboratory. Thus, an alkaline borate buffer was used
because of the complex formation between borates and
carbohydrates and the additional advantage that the anio-
nic borate disaccharide complexes formed have a higher
UV absorbance than the free anions of the disaccharides
[18, 40]. The impact of several experimental parameters,
including the concentration of the cationic surfactant that
is reversing EO, the pH and concentration of the running
buffer, and the separation voltage, on the resolution of di-
HA and di-CS was investigated using an aqueous sample
containing about 2 lg/mL of each compound and electro-
kinetic sample injection. A typical electropherogram
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together with its current profile are presented in Fig. 2A
and B, respectively. The sample solution contained 2 lg/
mL of di-CS (standard compound) and about an equiva-
lent amount of di-HA that was enzymatically derived from
HA using chondroitinase ABC. As the HA standard also
contained CS, the CS peak became somewhat increased.
Furthermore, the peaks detected around 6 min could be
those of sulfated disaccharides of CS [26].
There are two main reasons that are in favor of employing
CTAB as buffer additive. Firstly, CTAB is an EOF modifier
providing reversed EOF, which allows the use of electroki-
netic sample injection of anions with a long injection time
to improve the detection sensitivity. Secondly, via varying
the CTAB concentration, the use of this cationic surfactant
below its critical micellar concentration was found to
improve the resolution of the negatively charged disac-
charides of HA and CS. The data presented in Fig. 3 were
obtained with CTAB concentrations between 0.04 and
1.0 mM and show the impact of the CTAB concentration
on EO (Fig. 3A), the detection time of di-HA (Fig. 3A), and
the resolution of the disaccharides of HA and CS (Fig. 3B)
using 25 mM Na2B4O7 (pH 9.5) as BGE. Resolution was
noted to be highest at the lowest CTAB concentration.
This can be explained with the increase of EO toward the
anode as the CTAB concentration is increased. Accord-
ingly, detection times and thus the time interval for separa-
tion decrease from about 25 to 5.9 min for 0.04 and 1 mM
CTAB, respectively. Furthermore, the electrophoretic
mobility of the two disaccharides might also be influenced
by virtue of ion-pairing effects between CTAB and the
negatively charged solutes as was previously investigated
for di-CS and oligosaccharides derived from hyaluronan
using tetrabutylammonium as ion-pairing agent [40].
Under the investigated conditions, CTAB concentrations
between 0.04 and 0.05 mM were found to provide com-
plete separation of the two disaccharides (Figs. 2A, 3B).
At 0.04 mM of CTAB, the electroosmotic mobility was esti-
mated to be 0.63610– 8m2/V6s (no reversal of EOF).
The use of CTAB concentrations a0.04 mM resulted in
electropherograms without the two disaccharide peaks
being detected within a time interval of 30 min. Thus,
0.05 mMCTAB which provided an electroosmotic mobility
of –4.31610– 8m2/V6s (Fig. 3A) was selected for our
project.
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Figure 2. (A) Electropherogram and (B) temporal behavior
of the current for the separation of di-CS and di-HA in pre-
sence of 0.05 mM CTAB. An aqueous sample with about
2 lg/mL of each disaccharide (di-HA from HA depolymerized
with chondroitinase ABC) was analyzed. Conditions: capil-
lary, 67 cm (60 cm to detector)675 lm ID; applied voltage,
–15 kV; detection wavelength, 232 nm; electrolyte, 25 mM
tetraborate, adjusted to pH 9.5 with NaOH; injection voltage
and time, –10 kV for 20 s. EO refers to electroosmosis.
Figure 3. Influence of the CTAB concentration on (A) EO
and detection time of di-HA, and (B) resolution of the disac-
charides of HA and CS. EO refers to electroosmosis. Experi-
mental conditions as for Fig. 2.
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The impact of the buffer composition on resolution of the
two disaccharides was studied via variation of buffer pH
and concentration and having 0.05 mM CTAB as buffer
additive (Fig. 4). The resolution was found to become lar-
ger upon increase of pH (Fig. 4A). Having a borate con-
centration of 25 mM, the two disaccharides are baseline
separated for pH F 9.5. A pH 10.0 buffer was further used
because this pH offers a compromise between optimal
resolution and buffer capacity. Both the resolution
(Fig. 4B) and migration times of the analytes of interest
increased upon increasing the buffer concentration. This
is due to a decrease in EOF. Having a borate concentra-
tion above 20 mM provided a resolution >1.5. Further-
more, the current increased as the borate concentration
was enhanced and reached about 129 lA for the 50 mM
buffer. At currents above 85 lA (30 mM tetraborate), an
instability of the system was noticed (slow increase of cur-
rent with time). Thus, 25 mM was selected as buffer con-
centration for all further experiments.
With a 25 mM Na2B4O7 (pH 10.0) BGE with 0.05 mM
CTAB, the influence of the separation voltage on the reso-
lution of the disaccharides of HA and CS, studied in the
range between –10 and –18 kV, was found to be small.
The resolution of the two disaccharides decreased with
the increase of the separation voltage, namely, from 2.71
to 2.32 for –10 and –18 kV, respectively. The current
increased from 46 to 92 lA. In order to avoid too high cur-
rents, a voltage of –12 kV was further used.
3.2 Sample stacking
To reach highest sensitivity, electrokinetic sample injec-
tion was used. The presence of chloride was found to
nicely enhance the stacking of di-HA, an effect that was
not noticed for di-CS (Fig. 5A). This difference in peak
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Figure 4. Influence of (A) pH and (B) tetraborate buffer con-
centration on resolution of the disaccharides of HA and CS.
Buffers were composed of (A) 25 mM tetraborate containing
0.05 mM CTAB (pH adjustment with addition of boric acid or
NaOH) and (B) tetraborate containing 0.05 mM CTAB and
adjusted to pH 10.0 with addition of NaOH. Other conditions
as in Fig. 2.
Figure 5. (A) Electropherogram and (B) temporal behavior
of the current obtained for analysis of 20 lg/mL of each di-
saccharide in 25 mM Tris-HCl (pH 7.5) using the optimized
experimental conditions given in Section 2.2. Inset to the
right in panel A depicts a 1.2 min time interval of the two di-
saccharide peaks with expanded x-axis and y-axis scales.
Inset to the left depicts data obtained with a sample contain-
ing the two disaccharides (2 lg/mL each) in water. EO refers
to electroosmosis.
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shape is not observed when the two disaccharides are
dissolved in water only (left inset in Fig. 5A; see also
Fig. 2A). The two disaccharides were injected with time
intervals from 5 to 80 s using a sample with 2 lg/mL of
each disaccharide dissolved in 25 mM Tris-HCl (pH 7.5).
The influence of sample injection time on peak area, peak
height, the number of theoretical plates (N), the resolution
between the two disaccharides, and the corrected peak
area (peak area divided by detection time) is shown with
the data presented in Table 1. As expected, an increase
of the injection time led to higher peak areas, peak
heights, and corrected peak areas for both compounds.
The resolution between the two disaccharides and the
peak efficiency of di-CS, however, became lower.
Furthermore, contrary to the trend observed with di-CS,
the peak efficiency of di-HA was found to increase as the
injection time interval was enhanced up to 80 s. An injec-
tion greater than 60 s, however, was inappropriate
because of the resolution. Therefore, 40 s was selected
as the sample injection time (Fig. 5A). Using hydrody-
namic sample injection, the detection sensitivity was
found to be more than ten-fold worse (data not shown).
Furthermore, field-amplified sample injection with applica-
tion of a water plug prior to electroinjection from the sam-
ple dissolved in a low conductivity environment (water), as
was previously documented to provide over 1000-fold
sensitivity enhancement in other configurations [41], pro-
vided higher peaks for di-CS and di-HA (data not shown).
This approach, however, was not effective with samples
of high ionic strength, including the serum samples pre-
pared in this work, and was thus not further investigated.
Upon analysis of depolymerized HA in samples prepared
from human serum, the peak of di-HA was found to be
extremely narrow (see below). This high efficiency was
already noticed for the sample dissolved in Tris-HCl buffer
(Table 1, Fig. 5A). In the absence of chloride, however,
broader peaks were observed (left inset in Fig. 5A). Chlor-
ide and phosphate present in serum were previously iden-
tified as being beneficial for the stacking of analytes of like
charge for which they act as transient stackers [33, 34].
These two anions were also found to enhance the stack-
ing of the two disaccharides. Figure 6 shows data of peak
width at half height (W1/2) for samples of the two disac-
charides in 25 mM Tris-HCl (pH 7.5) that were fortified
with chloride (addition of NaCl, Fig. 6A) and phosphate
(addition of KH2PO4, Fig. 6B). Without addition of NaCl,
the chloride concentration in the sample was calculated to
be 18.7 mM. Best stacking was obtained with addition of
>10 mM chloride (total chloride concentration in the sam-
ple >28.5 mM) or F1 mM phosphate. Thus, the presence
of chloride and phosphate in the serum (100 and 0.5–
2 mM, respectively [34]) appears to be sufficient for the
stacking of the disaccarides. More experimental work has
to be conducted to identify the stacking mechanisms
involved, particularly the more efficient stacking of di-HA
compared to di-CS (Fig. 5A). In addition to sample self-
stacking, it may very well be that sweeping with borate
[37, 38] and/or pH induced stacking [35, 39] contribute to
solute concentration as well.
3.3 Linearity, reproducibility, and detection limits
Under optimized conditions, the electroosmotic mobility
was determined to be –4.06610– 8m2/V6s (Fig. 5A). As
the calibration range used was rather large, the linear rela-
tionship between the concentration of analytes and their
corresponding corrected peak area was established in
two ranges, namely, from 1.0 to 400 lg/mL and from 0.1
to 1.0 lg/mL (0.2–1.0 lg/mL for di-CS, see Table 2). The
samples with the two disaccharides were prepared in
25 mM Tris-HCl at pH 7.5, i. e., the buffer used for the
chondroitinase digestion of HA in serum (Section 2.3),
and analyzed under the optimized conditions (Fig. 5).
Regression analysis yielded straight lines with r >0.993
(Table 2). Reproducibility was determined by nine succes-
sive injections of a standard disaccharide solution within
1 day. For a sample with 10 lg/mL of each disaccharide,
a good accuracy for the detection times and corrected
peak areas was found with RSD being less than 1.3 and
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Table 1. Influence of the injection time of the sample on peak size, theoretical plates, and resolutiona)b)
Injection
time, s
Peak area Peak height N Rs Corr. areac)
di-CS di-HA di-CS di-HA di-CS di-HA di-CS di-HA
10 1184 2554 296 656 121 237 168 172 2.418 102 214
20 2560 5060 639 1534 112 745 253 140 2.351 220 425
40 5528 10 324 1233 3550 94 207 372 240 2.012 483 883
60 8088 14 922 1530 5248 68 244 426 656 1.538 722 1309
80 11 420 22 408 1800 6082 47 380 423 880 1.044 988 1908
a) Experimental conditions as stated in Section 2.2 and Fig. 5A using a sample composed of 2 lg/mL of each disaccharide in
25 mM Tris-HCl, pH 7.5.
b) Mean values (n = 3).
c) Peak area/detection time.
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2.2%, respectively (Table 2). The detection limits (S/N
= 3) of di-CS and di-HA were determined to be 0.10 and
0.075 lg/mL, respectively.
3.4 Analysis of di-HA in human serum after
enzymatic depolymerization of HA
Chondroitinase ABC depolymerized HA in the serum of a
healthy subject was analyzed with the optimized method
and the obtained electropherogram is presented in Fig.
7B. The assigned peaks were identified by spiking the
sample with the standards of di-HA and di-CS followed by
reanalysis. Furthermore, based on the work of Karama-
nos and Hjerpe [26], the peak marked with an asterisk in
Fig. 7B could represent a sulfated disaccharide of CS.
The identity of all other peaks is unknown. Using the cali-
brations discussed above that are based on corrected
peak areas, the amount of di-HA in this serum was esti-
mated as being 3.03 € 0.16 lg/mL (average of three
experiments). Similar results were obtained with other
samples. Although a more accurate value could possibly
be obtained via calibration with standard additions of di-
HA to the prepared serum sample prior to reanalysis, this
approach was not investigated as the di-HA levels found
are more than one order of magnitude higher than
expected. According to the protein binding assays used
routinely in clinical laboratories [17], serum HA levels of
normal subjects should be lower than about 100 ng/mL.
Thus, not surprisingly, the di-HA peaks determined for the
depolymerized serum samples were found to contain
other tightly stacked compounds that comigrated with di-
HA (denoted with letter I in Fig. 7). This could unambigu-
ously be proven by analysis of the serum without chon-
droitinase ABC depolymerization, i. e., during sample pre-
paration, the Tris-HCl buffer was added without the
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Figure 6. Influence of (A) chloride addition and (B) phos-
phate concentration in the sample on peak width at half
height (W1/2). Sample was composed of 10 lg/mL of the two
disaccharides in 25 mM Tris-HCl (pH 7.5) and was fortified
with NaCl or NaH2PO4 as indicated. Experimental conditions
as for Fig. 5.
Figure 7. Electropherograms obtained for analysis of the
serum of a healthy person (A) without enzymatic depolymer-
ization but otherwise the same sample pretreatment and (B)
after chondroitinase ABC depolymerization as described in
Section 2.3. di-HA content was estimated to be 0.46 lg/mL.
Current data are presented in panel C (dotted and solid lines
for blank and depolymerized serum, respectively). Peak
denoted with the letter I refers to a blank peak that interferes
with the detection of di-HA. Experimental conditions as in
Section 2.2.
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enzyme. A blank electropherogram is presented in Fig.
7A. The interfering blank peak (peak I in Fig. 7A) was
found to be smaller compared to that detected after enzy-
matic depolymerization, thus permitting the di-HA content
to be estimated via blank subtraction (subtraction of area
of peak I of Fig. 7A from area of peak “di-HA + I” of Fig.
7B). For the example depicted in Fig. 7, the di-HA concen-
tration was thereby determined to be 0.46 lg/mL. Using
the Corgenix protein binding assay, the same serum
revealed an HA level of 21 ng/mL. More work is required
to provide insight into the difference of these results.
With samples prepared from different sera, the detection
times of di-HA containing peaks were found to vary from
sample to sample (between about 17 and 23 min),
between sample and its blank (Fig. 7A and B), and to be
significantly different to those observed with the standards
in the Tris-HCl buffer (compare data of Figs. 5A, 7B). Dif-
ferences in the sample matrices are believed to be
responsible for this variation. For the analysis of samples
containing various amounts of di-HA in the Tris-HCl buf-
fer, the detection time intervals were found to be constant
(Table 1; around 10 min, Fig. 5A). The recovery of di-HA
was determined by addition of known amounts of the di-
HA standard substance into the digested and reconsti-
tuted human serum sample. Forty microliters of 100 lg/
mL di-HA in Tris-HCl (pH 7.5) and 40 lL of depolymerized
and reconstituted human serum sample were mixed and
analyzed. The mean (n = 6) recovery of di-HA and RSD
were calculated to be 92.4 and 3.01%, respectively. The
mean detection time and RSD were 14.66 min and
1.69%, respectively. The detection time is between those
of the standards in Tris-HCl (Fig. 5A) and the patient sam-
ple (Fig. 7B), again indicating the impact of the sample
matrix on the detection time.
Based upon the presented data, it is clear that di-HA in the
prepared serum samples cannot be determined by CE
without further simplification of the sample matrix. In our
laboratory, efforts are currently being undertaken to inves-
tigate the nature of the endogenous compounds that
comigrate with di-HA and to find effective means to elimi-
nate the interfering blank peak. These results will be pre-
sented in an upcoming communication.
4 Concluding remarks
In conclusion, the investigated capillary electrophoretic
method featuring a tetraborate buffer at pH 10, reversed
polarity, and reversed EO is shown to provide good reso-
lution of the nonsulfated disaccharides of HA and CS in
model samples and serum digested with chondroitinase
ABC. Electrokinetic injection from a sample dissolved in
25 mM Tris-HCl (pH 7.5) is demonstrated to provide a
sharply stacked di-HA peak that can accurately and reli-
ably be quantitated based upon corrected peak areas.
With sample application at –10 kV for 40 s, the detection
limit for di-HA is 0.075 lg/mL. Analysis of enzymatically
depolymerized HA in human serum revealed a sharp
peak containing di-HA and endogenous interferences
such that the di-HA content could only be estimated via
subtraction of the blank peak obtained with the undepoly-
merized serum. For direct analysis of di-HA, investiga-
tions leading to samples without comigrating interfer-
ences have to be undertaken.
This work was partly supported by the Swiss National
Science Foundation.
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